NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Price, News & Analysis

SCYNEXIS logo
$2.86 +0.01 (+0.35%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About SCYNEXIS Stock (NASDAQ:SCYX)

Advanced

Key Stats

Today's Range
$2.70
▼
$2.93
50-Day Range
$2.85
▼
$5.37
52-Week Range
$2.70
▼
$9.12
Volume
48,137 shs
Average Volume
130,315 shs
Market Capitalization
$28.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Hold

Company Overview

SCYNEXIS, Inc. is a biotechnology company focused on developing antifungal medicines for infections that can be difficult to treat. Its research has centered on ibrexafungerp, an antifungal from the triterpenoid class that works through a mechanism distinct from that of commonly used azole antifungals.

Ibrexafungerp was approved by the U.S. Food and Drug Administration as Brexafemme for treating vulvovaginal candidiasis and later for reducing recurrent episodes of the condition. SCYNEXIS licensed rights to the drug to GSK under an agreement covering its development and commercialization.

The company’s work has also included exploring ibrexafungerp for other fungal infections, including serious invasive infections. Its regulatory history and commercial relationships have been centered primarily on the United States; SCYNEXIS has not been described here as having a broad direct-sales presence.

AI Generated. May Contain Errors.

SCYNEXIS Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

SCYX MarketRank™: 
2.33968804159 of 5 stars

SCYNEXIS scored higher than 47% of companies evaluated by MarketBeat, and ranked 582nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SCYNEXIS has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    SCYNEXIS has a consensus price target of $33.00, representing about 1,057.9% upside from its current price of $2.85.

  • Amount of Analyst Coverage

    SCYNEXIS has only been the subject of 1 research reports in the past 90 days.

  • Read more about SCYNEXIS's stock forecast and price target.
  • Earnings Growth

    Earnings for SCYNEXIS are expected to grow in the coming year, from ($3.48) to ($0.37) per share.

  • Price to Book Value per Share Ratio

    SCYNEXIS has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.72% of the float of SCYNEXIS has been sold short.
  • Short Interest Ratio / Days to Cover

    SCYNEXIS has a short interest ratio ("days to cover") of 5.55.
  • Change versus previous month

    Short interest in SCYNEXIS has recently increased by 7.07%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    SCYNEXIS does not currently pay a dividend.

  • Dividend Growth

    SCYNEXIS does not have a long track record of dividend growth.

  • News Sentiment

    SCYNEXIS has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for SCYNEXIS this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SCYNEXIS insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.09% of the stock of SCYNEXIS is held by insiders.

  • Percentage Held by Institutions

    54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about SCYNEXIS's insider trading history.
Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SCYX Stock News Headlines

FY2026 EPS Forecast for SCYNEXIS Reduced by Analyst
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
SCYNEXIS (NASDAQ:SCYX) Cut to "Sell" at Wall Street Zen
See More Headlines

SCYX Stock Analysis - Frequently Asked Questions

SCYNEXIS's stock was trading at $5.0592 at the start of the year. Since then, SCYX shares have decreased by 43.7% and is now trading at $2.85.

SCYNEXIS, Inc. (NASDAQ:SCYX) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.01. The firm earned $130 thousand during the quarter, compared to analysts' expectations of $130 thousand.

Shares of SCYNEXIS reverse split before market open on Monday, June 1st 2026.The 1-8 reverse split was announced on Friday, May 22nd 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

SCYNEXIS (SCYX) raised $62 million in an IPO on Thursday, April 3rd 2014. The company issued 6,200,000 shares at a price of $10.00 per share.

Top institutional investors of SCYNEXIS include Great Point Partners LLC (9.49%).
View institutional ownership trends
.

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Matinas Biopharma (MTNB), NVIDIA (NVDA), Micron Technology (MU), Viking Therapeutics (VKTX) and NIO (NIO).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SCYX
CIK
1178253
Employees
29
Year Founded
2000

Price Target and Rating

High Price Target
$33.00
Low Price Target
$33.00
Potential Upside/Downside
+1,053.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.44)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.61 million
Net Margins
N/A
Pretax Margin
-53.50%
Return on Equity
-39.29%
Return on Assets
-30.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.57
Quick Ratio
7.57

Sales & Book Value

Annual Sales
$20.60 million
Price / Sales
1.38
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.93 per share
Price / Book
0.48

Miscellaneous

Outstanding Shares
9,950,000
Free Float
9,546,000
Market Cap
$28.47 million
Optionable
Optionable
Beta
1.15

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:SCYX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners